Lisa Miller | executive |
Richard Hawkins | executive |
John McKew | executive |
Lori Lawley | executive |
Catherine Novack | analyst |
Pisit Pitukcheewanont | executive |
Leland Gershell | analyst |
Charles Duncan | analyst |
Good afternoon, and welcome to Lumos Pharma's Second Quarter 2024 Financial Results and Clinical Program Update Call. [Operator Instructions] This conference call is being recorded. I will now turn the call over to Lisa Miller, Vice President of Investor Relations.
Thank you, Operator.
Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S.